

Flu Product Reclassification

Consolidated

Quarter/Year	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Sofia 2 Flu + SARS Antigen FIA	\$ -	\$ 273,453,769	\$ 11,218,942	\$ 307,553	\$ 4,307,319
Influenza	\$ 8,973,743	\$ 32,333,454	\$ 5,180,754	\$ 1,313,363	\$ 9,530,750
Total	\$ 8,973,743	\$ 305,787,223	\$ 16,399,696	\$ 1,620,916	\$ 13,838,069

Domestic

Quarter/Year	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Sofia 2 Flu + SARS Antigen FIA	\$ -	\$ 273,001,369	\$ 11,189,440	\$ 269,553	\$ 3,923,409
Influenza	\$ 8,393,550	\$ 30,474,099	\$ 4,113,222	\$ 941,707	\$ 8,507,323
Total	\$ 8,393,550	\$ 303,475,468	\$ 15,302,662	\$ 1,211,260	\$ 12,430,732

Rest of World

Quarter/Year	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021
Sofia 2 Flu + SARS Antigen FIA	\$ -	\$ 452,400	\$ 29,502	\$ 38,000	\$ 383,909
Influenza	\$ 580,193	\$ 1,859,355	\$ 1,067,532	\$ 371,656	\$ 1,023,427
Total	\$ 580,193	\$ 2,311,755	\$ 1,097,034	\$ 409,656	\$ 1,407,336

Note: Q4 2020 was the first quarter Quidel sold the Sofia 2 Flu + SARS Antigen Combo test.